Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro

Sandra D Mulder1, Henrietta M Nielsen, Marinus A Blankenstein

  • 1Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands; Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.

Glia
|January 22, 2014
PubMed

Insights

Glial cells, astrocytes and microglia, clear amyloid-beta differently. Amyloid-associated proteins like ApoE and ApoJ hinder this clearance, suggesting therapies targeting these protein interactions could improve Alzheimer

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pathology

Background:

  • Defective amyloid-beta (Aβ) clearance contributes to Alzheimer's disease (AD) pathogenesis.
  • Astrocytes and microglia are key glial cells involved in Aβ clearance.
  • Amyloid-associated proteins (AAPs) may influence Aβ clearance by glial cells.

Purpose of the Study:

  • To investigate differential uptake efficiency of Aβ oligomers (Aβoligo) and fibrils (Aβfib) by astrocytes and microglia.
  • To determine if Aβ aggregation state and/or AAPs affect Aβ uptake in these glial cells in vitro.
  • To explore potential therapeutic strategies targeting Aβ-AAP interactions for enhanced Aβ clearance.

Main Methods:

  • Primary adult human microglia and astrocytes were isolated from post-mortem brain tissue.
  • Cells were exposed to Aβoligo or Aβfib, alone or with specific AAPs (ApoE, ApoJ, ACT, SAP-C1q).
  • Aβ-positive cells were quantified using flow cytometry.

Main Results:

  • Astrocyte uptake of Aβoligo was reduced in the presence of AAPs, while microglial uptake was unaffected.
  • Microglial uptake of Aβfib was significantly reduced by AAPs, whereas astrocytic uptake remained unchanged.
  • These findings indicate distinct roles for astrocytes and microglia in Aβ clearance and highlight negative impacts of AAPs.

Conclusions:

  • Astrocytes and microglia exhibit differential Aβ uptake efficiencies for oligomeric and fibrillar forms.
  • AAPs, including ApoE and ApoJ, negatively modulate Aβ clearance by glial cells.
  • Targeting Aβ-AAP interactions presents a potential therapeutic avenue to enhance glial Aβ clearance in AD.